Intravitreal Bevacizumab in the treatment of neovascular glaucoma secondary to central retinal vein occlusion: a case report

INTRODUCTION: Every eye with central retinal vein occlusion (CRVO) is at risk for developing neovascular glaucoma (NVG). Vascular endothelial growth factor (VEGF) has been shown to play a key role in the development of NVG in CRVO. Bevacizumab (Avastin; Genentech, San Francisco, CA) is a recombinant...

Descripción completa

Detalles Bibliográficos
Autores principales: Alasil, Tarek, Rauser, Michael E
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2783132/
https://www.ncbi.nlm.nih.gov/pubmed/19946487
http://dx.doi.org/10.1186/1757-1626-2-176

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2783132/
https://www.ncbi.nlm.nih.gov/pubmed/19946487
http://dx.doi.org/10.1186/1757-1626-2-176

Ejemplares similares